This is a study designed to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain.

The aim of this trial is to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain. Participants will include individuals with chronic pain, who will be randomized into one of two intervention conditions: low THC/high CBD or placebo. In addition to receiving CBD or placebo, participants also will complete symptom assessments of chronic pain data (intensity, quality, interference/disability) throughout the study. These measures will be gathered prior to and following the fifth doses (dosing will occur once per day for five days) of CBD or placebo. A secondary objective will be to examine the association between clinical and inflammatory markers.

Inclusion Criteria:

• Age between 18-50 yrs.
• Chronic musculoskeletal and joint pain for at least 3 months or longer.
• Participants must live within a 60 mile radius of Salt Lake City, Utah to be eligible.

Exclusion Criteria:

• Current or past neurological illness.
• Substance abuse or dependence within the prior 90 days.
• Contraindication to brain MRI.
• Type I and type II diabetes.
• Unstable medical conditions.
• Consumption of more than 2 drinks of alcohol per night.
• Current pregnancy or planning to become pregnant or breastfeeding.
• History of seizures or head trauma at PI discretion.
• Active or history of major mental illness
• Use of opioid medications in the past 30 days.
• LFT results 3 times greater than the upper limit of normal at the screening.
• Participants may be excluded if the PI feels they do not meet safety criteria.

The investigators are still deciding on if and what IPD will be shared and the details involved. The investigators will update when a plan is in place.